Sinovac Biotech Ltd. (SVA) Announces SFDA Approval to Commence Clinical Trials for Enterovirus Type 71 Vaccine

QualityStocks would like to highlight Sinovac Biotech Ltd. (NASDAQ: SVA), a China-based biopharmaceutical company that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza, and H1N1 influenza.

In the company’s news yesterday,

Sinovac Biotech Ltd. announced that it has received approval from the China State Food and Drug Administration (SFDA) to commence clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). Sinovac must conduct each phase of the human clinical trials in accordance with SFDA requirements, conduct studies to assess safety and immunogenicity in the phase I and II clinical trials, and conduct efficacy study in the phase III clinical trial. The company filed the application to commence human clinical trials for its inactivated EV71 vaccine in December of last year.

Dr. Weidong Yin, Chairman, President & CEO, stated, “We are very pleased to advance our near term vaccine development pipeline with the approval from the SFDA to commence clinical trials for our internally developed EV 71 vaccine. Currently, there is no vaccine available worldwide for this disease. We had no precedent to go by during the development, so we had to start with the basic research on this vaccine. Moreover, our R&D people has successfully completed pre-clinical research and made significant breakthroughs during the development. We will move forward with our research and development of vaccines with the objective to supply high quality vaccine products to children worldwide as soon as possible and to contribute to the prevention and control of HFMD.”

The Company began preclinical research for its independently developed EV 71 vaccine approximately two years ago. The animal model, built by researchers at Sydney University, showed cross protection and demonstrated that the vaccine is effective in animals. Sinovac has already filed five patent applications covering the EV 71 vaccine.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.